40th week of 2021 patent applcation highlights part 11 |
Patent application number | Title | Published |
20210308233 | PROTEINS HAVING PNEUMOCOCCAL CAPSULE DEGRADING ACTIVITY AND METHODS OF USE - Provided herein is a protein, referred to as a Pn3Pase protein, that degrades the capsular polysaccharide of serotype 3 | 2021-10-07 |
20210308234 | Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration - The present disclosure discloses compositions comprising a hyaluronidase, devices comprising such compositions, as well as methods and uses employing such compositions and devices to reduce or eliminate a hyaluronic acid-induced blockage of one or more blood vessels supplying an eye of an individual; methods and uses for employing such compositions and devices to reduce or inhibit a vascular occlusion in an eye of an individual; and methods and uses for employing such compositions and devices to reduce or inhibit a hyaluronic acid-induced loss of vision of an individual. | 2021-10-07 |
20210308235 | ENZYMES AND METHODS FOR CLEAVING N-GLYCANS FROM GLYCOPROTEINS - Provided herein are deglycosylating enzymes that remove a broad range of N-glycans from N-glycosylated proteins. Further provided are methods of recombinantly producing and expressing the deglycosylating enzymes. The presently described deglycosylating enzymes can be used to produce free glycans for characterization, and for prebiotic and immunostimulatory uses. In addition, the presently described deglycosylating enzymes can be used to produce deglycosylated proteins for characterization, to improve digestion, and to reduce immunogenicity. | 2021-10-07 |
20210308236 | BOTULINUM TOXIN AND THE TREATMENT OF PRIMARY DISORDERS OF MOOD AND AFFECT - The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin. | 2021-10-07 |
20210308237 | RECOMBINANT L-ASPARAGINASE - The present invention provides compositions and methods for treating a disease treatable by asparagine depletion in a human subject comprising administering to a human subject a recombinant L-asparaginase. | 2021-10-07 |
20210308238 | INJECTION SOLUTION FOR RNA - The invention relates to the use of RNA and an aqueous injection buffer containing a sodium salt, a calcium salt and optionally a potassium salt and optionally lactate, in the preparation of a RNA injection solution for increasing RNA transfer and/or RNA translation into/in a host organism. The invention relates further to a RNA injection solution and to a method for increasing the RNA transfer and/or RNA translation of RNA in vivo and in vitro. | 2021-10-07 |
20210308239 | THERAPEUTIC INDUCTION OF TOLERANCE USING RECOMBINANT CELL SURFACE ANTIGENS - Compositions and methods for the induction of tolerance using recombinant cell surface antigens in a vertebrate subject are provided. | 2021-10-07 |
20210308240 | POLYPEPTIDE USEFUL IN ADOPTIVE CELL THERAPY - The present invention provides a polypeptide having the formula: St-R1-S1-Q-S2-R2 wherein St is a stalk sequence which, when the polypeptide is expressed at the surface of a target cell, causes the R and Q epitopes to be projected from the cell surface; R1 and R2 are a Rituximab-binding epitopes each having the an amino acid sequence selected from the group consisting of SEQ ID No. 1, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16 or a variant thereof which retains Rituximab-binding activity; S1 and S2 are optional spacer sequences, which may be the same or different; and Q is a QBEnd10-binding epitope having the amino acid sequence shown as SEQ ID No. 2 or a variant thereof which QBEnd10-binding activity. The invention also provides a nucleic acid sequence encoding such a polypeptide and uses thereof in adoptive cell transfer. | 2021-10-07 |
20210308241 | DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY BY PD-1 BLOCKADE - Molecular determinants of cancer response to immunotherapy are described, as are systems and tools for identifying and/or characterizing cancers likely to respond to immunotherapy. | 2021-10-07 |
20210308242 | FUSION PROTEINS COMPRISING AN ANTI-CD40 ANTIBODY AND CANCER ANTIGENS - The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies. | 2021-10-07 |
20210308243 | OPTIMIZED SYNTHETIC CONSENSUS IMMUNOGENIC COMPOSITIONS TARGETING CHONDROITIN SULFATE PROTEOGLYCAN 4 (CSPG4) - Provided herein is an immunogenic composition comprising a synthetic consensus antigen to chondroitin sulfate proteoglycan 4 (CSPG4) protein which is abundant in many cancers. Also disclosed herein is a method of treating a tumor associated pathology in a subject in need thereof, by administering the immunogenic composition to the subject. | 2021-10-07 |
20210308244 | IMMUNOGENIC COMPOSITIONS, ANTIGEN SCREENING METHODS, AND METHODS OF GENERATING IMMUNE RESPONSES - An immunogenic composition is provided herein. The immunogenic compositions are used to identify and select immunogenic antigens that elicit immune responses in a subject and may be subsequently used in multi-antigen vaccine compositions against one or more diseases or conditions. According to some embodiments, the immunogenic composition may include a plurality of nucleic acid fragments or minigenes derived from a nucleic acid library, wherein each nucleic acid fragment encodes a different antigen or functional portion thereof, and wherein the different antigens or functional portions thereof are associated with one or more disease or condition. The immunogenic composition may also include a delivery medium loaded with the plurality of nucleic acid fragments and in some embodiments, the delivery medium is loaded with nucleic acid fragments in such a way that individual antigen presenting cells receive only a subset of the nucleic acids within a vaccine in order to minimize antigenic competition. | 2021-10-07 |
20210308245 | CONSTRUCTION AND USE OF TANDEM EPITOPE POLYPEPTIDE OF OUTER MEMBRANE PROTEIN OF CAMPYLOBACTER JEJUNI, GENE, RECOMBINANT PLASMID AND RECOMBINANT BACTERIA - The disclosure provides the construction and use of tandem epitope polypeptide of outer membrane protein of | 2021-10-07 |
20210308246 | Modified tetra-acylated neisserial LPS - The present invention relates to neisserial LPS having a tetra-acylated lipid A moiety, wherein the tetra-acylated lipid A moiety is modified as compared to the lipid A moiety of a wild-type neisserial LPS in that it lacks one of the secondary acyl chains and lacks a primary acyl chain on the 3-position of the glucosamine at the reducing end of the lipid A moiety. The invention further relates to neisserial bacteria that have been genetically modified to reduce expression of either one of the endogenous lpxL1 or lpxL2 genes and to introduce expression of a heterologous pagL gene. The neisserial LPS of the invention has TLR4 agonist properties and is therefore useful in compositions for inducing or stimulating immune responses, such as vaccines, as well as in other forms of immunotherapy. | 2021-10-07 |
20210308247 | GNA1870-Based Vesicle Vaccines for Broad Spectrum Protection Against Diseases Caused by Neisseria Meningitidis - The present invention generally provides methods and compositions for eliciting an immune response against | 2021-10-07 |
20210308248 | ISOLATION OF A NOVEL PESTIVIRUS CAUSING CONGENITAL TREMOR A - The present invention relates to a new pestivirus useful in the fields of veterinary virology and vaccines. Specifically, it relates to an isolated polynucleotide originating from pestivirus and a pestivirus, to vaccines and medical uses thereof, to chimeric virus comprising the polynucleotide and to expression vectors for heterologous expression of polypeptides. | 2021-10-07 |
20210308249 | VLP FORMULATIONS - The present invention relates to an aqueous composition comprising water, virus like particles, at least one amino group containing mucoadhesive and at least one buffer. In certain embodiments, the virus like particles have a size average of no more than about 4 times the size average of a comparison sample of virus like particles without mucoadhesive in water. In certain embodiments, the virus like particles have a size average of no more than about 400 nm. In certain embodiments, the virus like particles have a positive zeta potential. | 2021-10-07 |
20210308250 | ZIKA VIRUS IMMUNOGENIC COMPOSITIONS - Provided herein are methods of use of subunit immunogenic compositions, in particular for the prevention and treatment of Zika vims infections. | 2021-10-07 |
20210308251 | AGENT FOR THE PREVENTION OF VIRAL INFECTIONS - The invention relates to medicine and veterinary medicine, and more specifically to pharmacology, and can be used to prevent viral infections caused be RNA viruses that have a lipid capcid. An agent for prevention viral infections comprises viral material from RNA viruses that have a lipid capcid and stabilized colloidal selenium at a 1:1 ratio. The viral material from RNA viruses has titres of 6.0-8.0 lg TCD | 2021-10-07 |
20210308252 | LIPOSOME COMPOSITIONS COMPRISING PAM2CYS OR PAM3CYS ADJUVANT AND METHODS FOR INDUCING A HUMORAL IMMUNE RESPONSE - The invention provides compositions comprising liposomes, an antigen capable of inducing a humoral immune response, a carrier comprising a continuous phase of a hydrophobic substance, and an adjuvant that activates or increases the activity of TLR2. The invention also provides uses for such compositions in inducing a humoral response and methods for their use in the treatment of a disease, disorder or ailment ameliorated by a humoral immune response. | 2021-10-07 |
20210308253 | NEW VACCINES AGAINST AVIAN REOVIRUSES - The present invention relates to vaccine and composition comprising at least one antigenic material derived from an avian reovirus and an adjuvant comprising a lipophile and a polymer of acrylic or methacrylic acid and uses thereof for vaccinating avian against reoviruses. | 2021-10-07 |
20210308254 | HUMAN ROTAVIRUS STRAINS AND VACCINES - A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine. | 2021-10-07 |
20210308255 | ZIKA VIRUS VACCINE - A recombinant vesicular stomatitits virus (rVSV) having a Zika virus (ZIKV) envelope (E) gene, a prime boost immunization combination against ZIKV including: (a) a prime vaccine or immunogenic composition comprising a recombinant vesicular stomatitis virus (rVSV) carrying a ZIKV envelope (E) protein, and (b) a boost vaccine or immunogenic composition comprising a rVSV carrying the same ZIKV E protein. The ZIKV gene can be genetically modified to encode a modified ZIKV E protein that elevates glycoprotein synthesis and trigger efficient humoral immune response. | 2021-10-07 |
20210308256 | SEQUENTIAL IMMUNIZATION STRATEGIES TO GUIDE THE MATURATION OF ANTIBODIES AGAINST HUMAN IMMMUNODEFICIENCY VIRUS - Sequential immunization strategies to guide the maturation of antibodies against the human immunodeficiency virus (HIV) are described. The sequential immunization strategies utilize an HIV envelope protein (Env) that binds germline (gl) B cells as a first (prime) immunization and an Env with a functional glycosylated N276 as a second (boost) immunization. The sequential immunization strategies successfully elicit neutralizing antibodies against HIV. | 2021-10-07 |
20210308257 | IMMUNOGENIC COMPOSITION AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) - The present invention relates to an immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially to an immunogenic composition having a recombinant SARS-CoV-2 S protein and adjuvant. | 2021-10-07 |
20210308258 | MICROCAPSULE-BASED VACCINE - A vaccine comprising antigen and a matrix of biodegradable polymer blend, wherein the polymer blend comprises hydrophobic polymer and amphiphilic block copolymer, and the vaccine exists in form of microcapsules that comprise a multi-cavity structure inside, and has an average particle diameter of preferably 10-100 μm and more preferably 30-60 μm, and is prepared by means of the following method: making porous microspheres from the polymer blend, then mixing the porous microspheres with antigen-containing solution, and then sealing openings of porous microspheres that have been loaded with the antigen-containing solution to form an opening-sealed microcapsule loaded with the antigen. | 2021-10-07 |
20210308259 | HYDROXYAPATITE POWDER AND PROCESS FOR PRODUCING SAME, COMPOSITION BASED ON THIS POWDER AND PROCESS FOR PREPARING SAME AND KIT COMPRISING THIS POWDER - The present invention relates to a hydroxyapatite and/or tricalcium phosphate powder characterized in that it has undergone at least one sintering step at a temperature between 400° C. and 600° C. The invention also relates to a process for preparing such a powder, and to a composition comprising such a powder for use as an anti-tumour auto-vaccine and particularly in the treatment of the following pathological conditions: osteosarcoma, B or T lymphoma, mammary tumour, melanoma, haemangiosarcoma, mastocytoma, fibrosarcoma, brain tumours and schwannoma in a subject. The present invention also covers a drug combination comprising the composition of the invention and at least one second therapeutic agent, preferably an anti-tumour agent and/or a radiotherapeutic agent. | 2021-10-07 |
20210308260 | Non-integrative Listeria-based vaccine and method for inducing antitumor immune response - Disclosed are a non-integrative | 2021-10-07 |
20210308261 | EGFR-DIRECTED CAR THERAPY FOR GLIOBLASTOMA - Glioblastoma (GB) remains the most aggressive primary brain malignancy; brain metastasis, such as breast cancer brain metastases (BCBMs), are also aggressive and are associated with poor prognosis. Adoptive transfer of chimeric antigen receptor (CAR)-modified immune cells has emerged as a promising anti-cancer approach, yet the potential utility of CAR-engineered cells to treat brain cancers has not been explored. The present disclosure presents compostions and methods for using CAR expressing cells in the treatment of various cancers, including brain cancers such as GB and BCBMs. | 2021-10-07 |
20210308262 | LIQUID PHARMACEUTICAL COMPOSITION - The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug. | 2021-10-07 |
20210308263 | SYSTEMS AND METHODS FOR THE LARGE SCALE ACTIVATION OF WATER AND METHODS OF USING ACTIVATED WATER - Large scale systems for the activation of water and other aqueous solution using molecular resonant effect technology. Methods of using activated liquids to affect biological systems, including the inhibition of tumor cell proliferation, NK cell mediated cytolysis of tumor cells, the prevention of amyloid plaques, the inhibition of microbial growth, and the prevention or reduction of viral and bacterial infection. The methods include administration of liquids subjected to molecular resonant effect technology to those in need thereof. | 2021-10-07 |
20210308264 | METHOD AND APPARATUS FOR TREATING BONE FRACTURES, AND/OR FOR FORTIFYING AND/OR AUGMENTING BONE, INCLUDING THE PROVISION AND USE OF COMPOSITE IMPLANTS, AND NOVEL COMPOSITE STRUCTURES WHICH MAY BE USED FOR MEDICAL AND NON-MEDICAL APPLICATIONS - A composite comprising: a barrier, said barrier being configured to selectively pass water, and said barrier being degradable in the presence of water; a matrix material for disposition within said barrier, wherein said matrix material has a flowable state and a set state, and wherein said matrix material is degradable in the presence of water; and at least one reinforcing element for disposition within said barrier and integration with said matrix material, wherein said at least one reinforcing element is degradable in the presence of water, and further wherein, upon the degradation of said at least one reinforcing element in the presence of water, provides an agent for modulating the degradation rate of said matrix material in the presence of water. | 2021-10-07 |
20210308265 | METHOD OF PREPARING AN ANTIBODY PHARMACEUTICAL FORMULATION - The present disclosure provides materials and methods for preparing an antibody pharmaceutical formulation having a viscosity of 10 cP or less comprising exchanging a composition comprising the antigen binding protein with a diafiltration buffer comprising calcium at a temperature greater than 30° C. | 2021-10-07 |
20210308266 | LIPOFULLERENE CONJUGATES AND THEIR USE FOR PROMOTION OF HAIR GROWTH AND PREVENTION OF HAIR LOSS - In some embodiments, a system and/or method may include a chemical composition which functions to promote hair growth and/or inhibits hair loss. The chemical composition may include a lipofullerene. The chemical composition may include activator. The activator may include a physiologically acceptable carrier. The lipofullerene may be applied to a subject separately from the activator. The lipofullerene may be applied to the subject first and the activator may be applied to the subject after in the same general area of the subject. | 2021-10-07 |
20210308267 | REJUVENATION OF CAR T CELL - A payload of drug conjugated to a targeting ligand specifically designed to deliver to exhausted CART cells to rejuvenate these CAR T cells is provided herein. The targeted CAR T cells are modified with a fusion receptor which can bind to the targeting ligand and internalize the conjugated payload of drug to execute its regulatory function to exhausted CAR T cell. | 2021-10-07 |
20210308268 | SYNTHESIS AND PROCESSING OF POLY(PRO-DRUG) MATERIALS FOR EXTENDED DRUG RELEASE AND USES THEREOF - The poly(pro-drug) material includes one or more alternating therapeutic compounds and biodegradable hydrocarbyl groups. The therapeutic compounds and biodegradable hydrocarbyl groups are separated by cleavable linker compounds. The therapeutic compounds, such as estrogen, curcumin, and fingolimod, include a plurality of substitutable functional groups that provide reaction sites for complexing with the cleavable linkers and in turn one or more polymers, such that the poly(pro-drug) material ends up composed of the therapeutic compound itself In aqueous media and at physiological temperature and pH, the poly(pro-drug) materials degrade to release the therapeutic compounds from the material with a zero-order release profile. Advantageously, the poly(pro-drug) materials release the therapeutic compounds on time scales of years. The poly(pro-drug) materials also exhibit reduced to allow for prolonged implantation within a patient. These materials are enticing for a myriad of biomedical applications, including veterinary medicine, cancer treatments, birth control, and hormone replacement therapy. | 2021-10-07 |
20210308269 | Small Molecule Drug Conjugates - A binding moiety (B) for Carbonic Anhydrase IX (CAIX), the binding moiety comprising: | 2021-10-07 |
20210308270 | SYSTEMS AND METHODS FOR INTRACELLULAR DELIVERY VIA NON-CHARGED SEQUENCE-DEFINED CELL-PENETRATING OLIGOMERS - The present disclosure provides oligoTEAs and methods of using the oligoTEAs. The oligoTEAs may be functionalized with one or more cargo group. The oligoTEAs may be made by iterative thiol-ene and Michael reactions. The oligoTEAs functionalized with one or more cargo group may be used to treat bacterial infections, cancers, viral infections, urinary tract infections, skin infections, cystic fibrosis, sepsis, fungal infections, or a combination thereof. | 2021-10-07 |
20210308271 | LIGAND CAPABLE OF MULTIVALENTLY BINDING TO GLUTAMINE TRANSPORTER, AND COMPOSITION COMPRISING SAME - The present invention pertains to a ligand that contains a plurality of groups represented by formula (1) and is capable of multivalently binding to a glutamine transporter expressed in excess in a cancer cell compared to a normal cell. | 2021-10-07 |
20210308272 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY - Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of a DMPK allele comprising a disease-associated-repeat. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide. | 2021-10-07 |
20210308273 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES - Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele. | 2021-10-07 |
20210308274 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FRIEDREICH'S ATAXIA - Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload increases FXN expression. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide. | 2021-10-07 |
20210308275 | Linkers and conjugates - A conjugate comprising a protein or a peptide, a linker and an active agent, wherein the linker comprises the moiety of formula (III): (III) wherein two of A | 2021-10-07 |
20210308276 | HETEROARYL SULFONE-BASED CONJUGATION HANDLES, METHODS FOR THEIR PREPARATION, AND THEIR USE IN SYNTHESIZING ANTIBODY DRUG CONJUGATES - The present invention is directed to novel heteroaryl sulfone-based conjugation handles of the formula: (wherein R | 2021-10-07 |
20210308277 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS - The present invention relates to linkers having a group of propiolyl, substituted acryl(acryloyl), or disubstituted propanoyl, and using such linkers for the conjugation of compounds, in particular, cytotoxic agents to a cell-binding molecule. | 2021-10-07 |
20210308278 | INTRANASAL VACCINE THAT INDUCES CELLULAR IMMUNITY - The present invention provides a nanogel nasal vaccine that induces cell-mediated immunity. Specifically, the present invention relates to a vaccine preparation comprising a complex of a nanogel, a vaccine antigen, and an adjuvant, wherein the vaccine preparation can efficiently induce the cell-mediated immunity, and can also induce a systemic and mucosal immune response. | 2021-10-07 |
20210308279 | SALVIANOLIC ACID-GELATIN CONJUGATE HYDROGEL PARTICLES - The present disclosure relates to salvianolic acid-gelatin conjugate load retentive hydrogel nanoparticles useful for oral delivery of salvianolic acid, pharmaceutical compositions comprising the same, and methods of use and preperation thereof. | 2021-10-07 |
20210308280 | Glyco-Metal-Organic Frameworks-based Hepatic Targeted Therapeutic Drug and Preparation Method Thereof - The disclosure discloses a glyco-metal-organic frameworks-based hepatic targeted therapeutic drug and a preparation method thereof, and belongs to the field of biomedicine. The disclosure loads a chemotherapeutic drug onto specific metal-organic frameworks, and modifies targeted molecule galactose on the surface of the materials through amide reaction. The biocompatibility and cytotoxicity of the obtained hepatic targeted therapeutic drug have been carefully evaluated at the cellular level. The hepatic targeted therapeutic drug of the disclosure has good stability and acidic pH triggered drug release property, and can exert the synergistic therapeutic effect of photodynamic therapy and chemotherapy. In addition, in vivo behavioral tracing and therapeutic efficacy are evaluated in mouse models with subcutaneous solid tumor and tumor in situ, and the disclosure is expected to play a huge role in clinical applications. | 2021-10-07 |
20210308281 | COMBINATION THERAPY FOR SPINAL MUSCULAR ATROPHY - Aspects of the application relate to compositions and methods for treating spinal muscular atrophy in a subject. In particular, this application provides therapeutic combinations of a recombinant nucleic acid that encodes the survival of motor neuron 1 (SMN1) protein (e.g., in a viral vector), and an antisense oligonucleotide (ASO) that increases full-length survival of motor neuron 2 (SMN2) mRNA (e.g., that is targeted to a nucleic acid molecule encoding the survival of motor neuron 2 (SMN2) and that promotes the inclusion of exon 7 in SMN2 mRNA). | 2021-10-07 |
20210308282 | GENE THERAPY DNA VECTORS BASED ON VTVAF17 - Produced the gene therapy DNA vectors based on the gene therapy DNA vector VTvaf17 for the treatment of diseases featuring disruption of mucociliary transport, mucolytic function and development of mucostasis. The gene therapy DNA vector contains the coding region of the SKI, TGFB3, TIMP2 or FMOD therapeutic genes. Methods of producing or use a gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying SKI, TGFB3, TIMP2 or FMOD therapeutic genes. The methods of producing strain for production of gene therapy DNA vector for treatment of diseases featuring disruption of mucociliary transport and development of mucostasis. | 2021-10-07 |
20210308283 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF - The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them. | 2021-10-07 |
20210308284 | METAL ATOM CLUSTER-EMBEDDED MAGNETIC IRON OXIDE NANOPARTICLE (MION), AND PREPARATION METHOD AND APPLICATION THEREOF - A metal atom cluster-embedded magnetic iron oxide nanoparticle (MION) is disclosed. The metal atom cluster is embedded in an iron oxide crystal matrix and has a content of 0.1% to 15%. A method for preparing the MION includes: dissolving a metal precursor of iron oxide, an organic acid, and an organic amine in an organic solvent to form a uniform reaction system; heating the reaction system to 150° C. to 350° C. in an inert gas atmosphere; adding a metal atom cluster precursor; and heating to perform a reflux reaction until the metal atom cluster precursor is completely decomposed. The MION shows improved magnetic properties due to the embedding of the metal atom cluster, and the iron oxide fully ensures the stability of properties of the nanoparticles. The nanoparticles are especially applicable to biomedical detection and therapy and other fields. | 2021-10-07 |
20210308285 | HSP90-TARGETED INFLAMMATION AND INFECTION IMAGING AND THERAPY - The present invention provides new methods for inflammation and infection imaging and related medical applications thereof. In some embodiments, the present invention provides a method for the diagnosis of inflammation and/or infection. In some embodiments, the present invention provides a method for the treatment or prevention of inflammation and/or infection. In some embodiments, the present invention provides methods for monitoring the effect of inflammation and/or infection treatment, and/or methods for monitoring an inflammation and/or infection treatment regimen. In some embodiments, the present invention provides a method for selecting subjects for an inflammation and/or infection treatment. In some embodiments, the present invention provides a method for determining the dosage of a drug for the treatment of inflammation and/or infection. | 2021-10-07 |
20210308286 | LONG-CIRCULATING PSMA-TARGETED PHOTOTHERANOSTIC AGENT - Theranostic probes comprising a porphyrin-based photosensitizer, a D-peptide linker, and a urea-based PSMA-targeting ligand and methods of their use for treating and/or imaging PMSA-expressing tumors are disclosed. | 2021-10-07 |
20210308287 | METHOD FOR EXTRACTION AND PURIFICATION OF 68GA - Disclosed herein are methods preparing a purified, carrier-free 68Ga solution. Tire present disclosure also provides systems for preparing a purified, carrier-free 68Ga solution. The present disclosure also provides compositions comprising the purified, carrier-free 68Ga solutions disclosed herein. Also provided are methods of administering compositions of the present disclosure to a patient in need thereof, for example, for imaging a disease or disorder, such as cancer. | 2021-10-07 |
20210308288 | Portable Self-Contained Disinfection Device - A portable self-contained disinfection device includes an enclosure and one or more ultraviolet C (UVC) light-emitting diode (LED) illuminators. The enclosure is configured to at least partially surround at least a portion of a user. The one or more UVC LED illuminators are disposed on the enclosure and configured to emit a UVC light toward the portion of the user surrounded by the enclosure. | 2021-10-07 |
20210308289 | INACTIVATION OF HIGHLY RESISTANT INFECTIOUS MICROBES AND PROTEINS WITH UNBUFFERED HYPOHALOUS ACID COMPOSITIONS - Methods for true sterilization of an object, methods for inactivating an infectious protein, and methods for inactivating a microbial pathogen using a bufferless, electrolyzed, hypohalous acid composition. | 2021-10-07 |
20210308290 | HAND SANITIZER DISPENSER - A system and method of use are provided for a hand sanitizer dispenser bottle. Disclosed herein is a system comprising a hand sanitizer dispenser bottle, including a reservoir configured to contain sanitizing liquid, an arm extending from the reservoir, a nozzle positioned on a lower surface of an upper portion of the arm, the nozzle configured for dispensing sanitizing liquid, and a sensor for detection the presence of a user's hand. In some embodiments, the nozzle is a dual-headed nozzle. | 2021-10-07 |
20210308291 | SYSTEM FOR FLUID STERILIZATION - A system of fluid sterilization of fluid of vessel is provided, such as sterilization of ballast water for a water vessel. The system incorporates a heating section to heat pressurized fluid above prescribed thresholds for temperature, pressure, and duration (e.g., dwell time) to achieve desired levels of sterilization, including a heat exchanger to both (a) preheat fluid prior to entering the heating section and (b) cool outflow of the heating apparatus, in which fluid travels through the apparatus by operating valves forward and aft of the heating section in a controlled sequence to facilitate flow through the system while maintaining prescribed pressure and temperature profiles. The system operates within prescribed ranges of pressure and temperature to achieve the desired level of sterilization without need of maintaining a fixed temperature or a fixed pressure within any portion of the system, including the heating section. | 2021-10-07 |
20210308292 | DEVICE AND METHOD FOR DEACTIVATING PATHOGENS IN BLOOD PLASMA, BLOOD PRODUCT AND BIOLOGICAL PRODUCT - Disclosed are methods and devices for reducing the number of pathogens in a liquid. The methods or devices uses one or more of pressure, pressure drop, increased temperature, rate of temperature increase, and inert gas to kill pathogens. In one embodiment, inert gas is dissolved into a liquid at a pressure greater than ambient pressure. The pressure is later rapidly reduced, which causes inert gas to be released from the liquid. This reduces the number of pathogens in the liquid. Other method steps or processes that do not utilize inert gas are also disclosed. | 2021-10-07 |
20210308293 | SAFEGUARDED GERMICAL LIGHTING DEVICE - A lighting device comprises a light head, two light sources, and a safeguard mechanism. The light head houses the two light sources. The first light source emits predominantly ultraviolet (UV) light (<400 nm) for germicidal illumination, and the second light source emits predominantly visible light (>400 nm) for general lighting. The lighting device may operate in two modes. The first operation mode is the general lighting mode, where the second light source is on for providing general lighting. The second operation mode is the germicidal lighting mode, where the first light source is on for providing germicidal lighting. The safeguard mechanism prevents the first light source in the germicidal lighting mode from turning on and causing accidental human exposure to the UV light from the first light source. | 2021-10-07 |
20210308294 | SYSTEM PERFORMING INACTIVATION OF MICROORGANISMS ON PAPER NOTES IN ATM WITH PULSED LIGHT TECHNOLOGY - The invention relates to a system which disinfects the microorganisms on the banknotes in ATM (automatic teller machine) machines. The invention is characterized by the application of the pulsed lights system ( | 2021-10-07 |
20210308295 | Ultraviolet Light Sanitizer - A sanitizing apparatus sanitizes headsets or eyeglasses between uses by patients. The apparatus includes a UV-C lamp that generates UV-C light at a proper frequency and intensity during a time period of sufficient duration to kill bacterial and viral infectants on surfaces of the headsets or eyeglass frames that may come in contact with a patient's skin. The apparatus may also be used for sanitizing bone vibrators, otoacoustic emissions testing equipment, headsets used in impedance testing, insert earphones, and response buttons that are commonly used in audiometric testing. The apparatus can also be used in communication situations in which headsets are utilized with microphones, such as in call centers. | 2021-10-07 |
20210308296 | SANITIZING CABINET FOR BANK TELLERS - An ultraviolet light (UV) sanitizing cabinet for banking equipment may include one or more UV light assemblies coupled to an electronics module and disposed within a housing. In some examples, the UV sanitizing cabinet may include racks or compartments configured to receive pneumatic tube canisters. In some examples, the UV sanitizing cabinet may include rollers or tumblers configured to rotate the pneumatic tube canisters to allow UV sanitization of all sides of the canisters. | 2021-10-07 |
20210308297 | AUTONOMOUS SANITIZATION MANAGEMENT, CONTROL AND DATA PLATFORM - An autonomous sanitization management, control and data platform (ASMCDP) for sanitizing an area includes an autonomous sanitization control center (ASCC) and one or more standalone autonomous sanitization (SAS) units communicatively coupled to the ASCC. Each of the one or more SAS units includes at least one sensor, a microcontroller communicatively coupled to the at least one sensor, and a light source coupled to the microcontroller. Power to the light source is selectively controlled by the microcontroller in response to a triggering signal emitted by the at least one sensor. When the light source is powered on, the light source emits sanitizing radiation. The one or more SAS units may be mounted within a vehicle to enable sanitization of the vehicle passenger compartment. | 2021-10-07 |
20210308298 | ULTRAVIOLET DEVICE - An ultraviolet device is provided, which includes a gas jetting module, a flow rate adjustment module, an ultraviolet module and a first gas channel. The gas jetting module includes an upper panel, a lower panel and a frame. The upper panel is disposed on the upper side of the frame. The lower panel is disposed on the lower side of the frame and includes one or more gas outlets. A gas chamber is formed between the upper panel, lower panel and frame. The first gas channel is connected to the gas jetting module. The flow rate adjustment module is connected to the first gas channel and adjusts the flow rate of the gas inputted into the gas chamber via the first gas channel. The ultraviolet module includes an ultraviolet light source and is connected to the gas jetting module. | 2021-10-07 |
20210308299 | DISINFECTING AND/OR STERILIZING DEVICE AND METHODS OF MAKING AND USING THE SAME - The presently disclosed subject matter is directed to a device configured to sterilize and/or disinfect one or more flat objects, such as (but not limited to) credit cards, identification cards, papers, business cards, currency, passports, and the like. The device includes a housing that comprises an internal compartment sized and shaped to house one or more objects. The internal compartment includes a plurality of bulbs (e.g., ultraviolet bulbs) positioned such that the entire surface of an object housed within the internal compartment is exposed to the bulbs. One or more objects can be at least partially positioned within the interior of the compartment via inlet and outlet slots. Thus, in use, an object enters the device interior via an inlet slot where it is exposed to the emitting bulbs. The sterilized and/or disinfected object then exits the device interior through exit slot where it can be used. | 2021-10-07 |
20210308300 | METHODS AND APPARATUS FOR SANITIZING AN AUTONOMOUS VEHICLE - According to one aspect, a vehicle includes a first compartment, a system, and a first sanitizing arrangement. The first compartment has a plurality of walls that define a space, and the system is configured to enable the vehicle to travel autonomously. The system includes a power system configured to provide power to the first compartment. The first sanitizing arrangement includes at least a first sanitizing component, the at least first sanitizing component being included in the first compartment, wherein the first sanitizing arrangement is configured to be activated to sanitize the plurality of walls and the space. | 2021-10-07 |
20210308301 | FOOD OR BEVERAGE CONTAINER SANITIZING SYSTEM - A sanitizing system for preventing the spread of harmful germs on food or beverage containers by utilizing a quick and compact UV sanitizing system. The doors of the pass-through chamber allow the customer to insert an un-sanitized container on the entry (“dirty”) side of the system, and the retail employee to remove the sanitized container from the exit (“clean”) side of the system without having to touch any other surface (doors, knobs, handles, etc.) than the container itself. The system utilizes movable UV light sources to minimize the time required for effective sanitizing. | 2021-10-07 |
20210308302 | SANITIZING DEVICE AND SYSTEM COMPRISING THE SAME - A sanitizing device is disclosed that has a channel extending through the device. The sanitizing device has a coupler for attaching it to a sewer cleaning machine for running its cable and/or cover tube through the channel. A set of ultraviolet LEDs illuminate the channel and disinfect the cable or cover tube running through the sanitizing device. Also, a system including a power transmission device and the sanitizing device is disclosed. | 2021-10-07 |
20210308303 | MEDICAL IMAGING DEVICE SUCH AS A TEE PROBE FOR UV DISINFECTION AND A DESIGN METHOD - This medical imaging device ( | 2021-10-07 |
20210308304 | STERILIZING COVER FOR TOUCHSCREENS COMPRISING UV EMITTING SOURCE - A touchscreen cover comprising a top side facing the user of a touchscreen, a bottom side facing the touchscreen and at least one UV emitting device or material for emitting energy having a wavelength ranging from 100-400 nm, that is in optical communication with the top side. A method of sterilizing a touchscreen by exposing a touchscreen cover to UV radiation for a time sufficient to deactivate or kill at least one microorganism found on the touchscreen. A method of coating a cover for touchscreen with a sterilizing composition is also disclosed. | 2021-10-07 |
20210308305 | UV SANITISATION DEVICE - The present disclosure is directed towards devices and methods for sanitising a receptacle or asap. In particular, this document describes a sanitisation device comprising a body having an opening configured to receive at least part of a receptacle or tap in use. The body contains one or more UV light sources. The body also comprises a guide, wherein the guide is shaped to position a portion of the surface of the receptacle or tap when the receptacle or tap is inserted into the opening of the body so that the portion is correctly located within the body for irradiation with UV light emitted by the one or more UV light sources, wherein the portion of the surface of the receptacle or tap that the guide is configured to position comprises an opening portion of the receptacle or tap. | 2021-10-07 |
20210308306 | OPERATOR SHIELDED MANUALLY TRANSPORTABLE ULTRAVIOLET DISINFECTION CART - A mobile body is configured to travel an area optionally over a surface inside an aircraft cabin. Components comprise at least one of a UVC protective shield, the shield selectively providing a multisided enclosure that selectively envelopes and/or separates the operator from the UVC in the surrounding environment. A source of UV radiation is mounted to the mobile body and configured to direct UV radiation to the surface at a predetermined dosage. At least two articulated arms are mounted to the mobile body, and UV lamps mounted respectively on the arms. The mobile body is a trolley or cart for negotiating an area optionally an aircraft aisle. | 2021-10-07 |
20210308307 | STERILIZATION MODULE - A sterilization module includes a main body having an opening on the top surface thereof, a transparent member which is arranged on the inside of the main body so as to cover the opening, and through which light passes, an inner sealing member which is made of an elastic material and which covers the side surface of the transparent member, a light emitting module that comprises a substrate and a light emitting element installed on the upper surface of the substrate, and which emits light through the transparent member, and an inner holder which is fastened to the inner side surface of the main body and fixes the light emitting module to the inside of the main body. | 2021-10-07 |
20210308308 | SYRINGE AND KIT FOR INTRAVESICAL USE - The present invention relates to a method for producing a sterile oxybutynin-comprising composition in a preferably ready-to-use piston syringe or for producing a preferably ready-to-use sterile piston syringe filled with an oxybutynin-comprising composition as well as a sterile oxybutynin-comprising composition and piston syringe as such. | 2021-10-07 |
20210308309 | METHODS OF DISARMING VIRUSES USING REACTIVE GAS - A method of disinfecting a surface that is contaminated with a virus or suspected of contamination with a virus, including: producing a reactive gas by forming a high-voltage cold plasma (HVCP) from a working gas with a dielectric barrier discharge (DBD) system at a voltage of 20 kV to 150 kV; transporting the reactive gas at least 1 meter away from the HVCP; followed by contacting the surface with the reactive gas. | 2021-10-07 |
20210308310 | SANITIZATION BOOTH - A sanitization apparatus is provided. The sanitization apparatus includes a framework providing a sanitizing zone shaped and dimensioned to permit a person to pass therethrough while being sprayed with sanitizer; a plurality of sprayers arranged on the framework for spraying a sanitizer into the sanitizing zone to allow substantial sanitization of an outer surface of a person; a supply of sanitizer, including a liquid container for the sanitizer, wherein the liquid container is in a predetermined position relative to the orientation of the apparatus; and a flow communication unit for allowing flow communication between the sprayers and the supply of sanitizer via a fluid displacement unit. | 2021-10-07 |
20210308311 | DECONTAMINATION ROOM AND METHOD OF CONTROLLING DECONTAMINATION - Disclosed are systems and processes that are usable to disinfect a room. | 2021-10-07 |
20210308312 | RACK FOR TREATMENT OF RESPIRATORY MASKS - A rack for sanitizing or cleaning medical or personal protective equipment is claimed herein. The rack has at least two stringers that run the length of the rack. The rack has at least two vertical grates that are spaced apart from each other along the stringers. The spacing between the grates will be sufficient such that a standard respiratory mask (e.g. N95) may be placed between two adjacent grates and be held in a vertical orientation. | 2021-10-07 |
20210308313 | DEVICE FOR ISOLATION, CLEANING, DRYING, DECONTAMINATION AND SANITIZATION OF CONTAMINATED COMPONENTS - The present invention relates to a device for isolating and cleaning contaminated components comprising a chamber, an entrance door through which components to be isolated and cleaned are introducible into the chamber, means configured to deliver washing solution into the chamber and onto the components to be cleaned, a drying system configured to dry the chamber as well as its content, wherein the device further comprises an exhaust filter system attached to the air exhaust of the chamber, the exhaust filter system comprising a pipe, at least one filter and a blower, the exhaust filter system being configured to be able to bring the chamber under a pressure lower than atmospheric pressure by means of the blower all the time the chamber is closed. The present invention also relates to a corresponding method for isolating and cleaning contaminated components with the aforementioned device. | 2021-10-07 |
20210308314 | Fragrance Carrier - A mechanism for holding a scented liquid capable of being carried on a person and discretely placed on the user, such as in a pocket, clipped to a person or worn on a chain. The mechanism, when activated by the user, allows for a flow of scent from the liquid to be either automatically heated or organically released in small quantities over time thereby allowing the user to keep a consistent scent on his or her person. The scent is released when heated by a heating means, or through organic contact with body heat, and slowly allowed to evaporate thereby dispersing the scent selected by the user. | 2021-10-07 |
20210308315 | Fragrance Fan - A fragrance fan includes a housing, a grille, a fan, a motor, and a power supply. The grille includes integrally formed fragrance medium receptacles for removably receiving and supporting fragrance medium members in an airstream produced when the motor rotates the fan about a fan axis. | 2021-10-07 |
20210308316 | Purified Hydrogen Peroxide Gas Generation Methods and Devices - The present disclosure provides for and includes improved devices and methods for the production of Purified Hydrogen Peroxide Gas (PHPG) that is substantially non-hydrated and substantially free of ozone. | 2021-10-07 |
20210308317 | TREATMENT APPARATUS FOR A VEHICLE TO TREAT AN OBJECT WITH ULTRAVIOLET LIGHT - A treatment apparatus for a vehicle comprises: a housing with at least one wall and a floor forming a treatment chamber; a source of ultraviolet light configured to emit ultraviolet light into the treatment chamber; and a door connected to the housing, the door having (i) an open position providing access to the treatment chamber and (ii) a closed position denying access to the treatment chamber and, together with the housing, preventing emitted ultraviolet light from irradiating beyond the treatment chamber. | 2021-10-07 |
20210308318 | WOUND DRESSING SYSTEM - A wound dressing system comprising a drape and a hydrogel sealant. The drape comprises a film and an adhesive on a first major surface of the film. The hydrogel comprises at least 30% by weight water, a crosslinked hydrophilic absorbent polymer; and a swelling agent. The hydrogel can create a seal between the drape and a surface (e.g., a patient's skin), making the disclosed systems suitable for negative pressure wound therapy (NPWT) applications. | 2021-10-07 |
20210308319 | TRANSITION TO TRANSLUCENT SUTURES - An absorbable medical article comprising:
| 2021-10-07 |
20210308320 | Self-Adhesive Multi-Fiber Materials - Provided is a multi-fiber system that undergoes new chemical bonds in response to mechanical manipulation and has self-adhesive properties based on specific chemical reactions. | 2021-10-07 |
20210308321 | BIODEGRADABLE POLYMER-CERAMIC BONE GRAFTS WITH OPEN SPIRAL STRUCTURES AND GRADIENT POROSITY AND METHODS FOR MAKING THEREOF - A scaffold has a spiral configuration and gradient porosity designed to facilitate the healing of bone injuries. To make the scaffold, a sheet of polymeric material or the like is rolled into a spiral shape. In one embodiment, the resulting scaffold has an outer porous layer with high porosity, and a comparatively less porous inner layer in order to facilitate vascularization and promote recovery. The pores can be filled with a degradable polymer and/or growth factors, bioactive molecules, bactericidal drugs and/or other compositions to further promote recovery. | 2021-10-07 |
20210308322 | VISCOELASTIC HYDROGELS WITH FAST STRESS RELAXATION - Provided are fast relaxing hydrogels that are useful for regulating cell behavior and enhancing tissue regeneration, e.g., bone regeneration. | 2021-10-07 |
20210308323 | COMPOSITION AND KITS FOR PSEUDOPLASTIC MICROGEL MATRICES - This invention relates generally to water-insoluble but water-swellable and deformable crosslinked PEGylated microgel particles of proteins and protein-based macromolecules that are pseudoplastic (shear thinning) and flow in aqueous media under shear and which can be injected or made to flow, wherein said microgel particles can reform as a cluster of microgel particles when shearing forces are removed. The microgel particles function as a matrix to support cell growth, viability, and proliferation. | 2021-10-07 |
20210308324 | METHOD FOR PRODUCING ZIRCONIA MATERIAL - A zirconia material manufacturing method includes: dispersing hydroxyapatite powder in water to prepare a slurry having a hydroxyapatite powder concentration of 1%; and dipping zirconia in the slurry to form, on the zirconia, a coating layer containing hydroxyapatite. | 2021-10-07 |
20210308325 | XENOTRANSPLANTATION PRODUCTS AND METHODS - A biological product for clinical xenotransplantation into a human and a method of preparing biological product for clinical xenotransplantation into a human involving producing a non-wild type, biologically engineered swine having a biologically engineered genome such that the swine does not express one or more extracellular surface glycan epitopes, is free of certain pathogens, is reared according to a bioburden-reducing procedure in a closed designated pathogen free herd, wherein the biological product is harvested following the swine being euthanized and the product is aseptically removed from the swine, the biological product is processed involving sterilization and storing the product in a sterile container, and the product does not contain one or more extracellular surface glycans, is free of certain designated pathogens, is biologically active and comprises live cells and tissues capable of vascularizing after xenotransplantation. | 2021-10-07 |
20210308326 | IMPLANTS TO INDUCE BONE REGENERATION AND USES THEREOF - Disclosed herein are compositions to facilitate bone growth, formation, and/or repair. Methods of using and making the compositions are also disclosed. | 2021-10-07 |
20210308327 | COMPOSITIONS AND METHODS USEFUL IN REGENERATIVE MEDICINE - The present invention relates in part to compositions and methods for treating a wound, or location of interest, in mammal by administering a decellularized extracellular matrix (ECM) lacking thrombospondin-2 (TSP-2-null ECM). In certain embodiments, the invention provides an acellular composition comprising a decellularized TSP-2-null ECM. In certain embodiments, the invention provides a tunable hydrogel comprising a decellularized TSP-2-null ECM. The invention also provides, in certain embodiments, methods for accelerating cellular migration, methods for enhancing cellular invasion, methods for enhancing vascular growth and maturation of a region to be treated, and/or methods for enhancing a wound repair in a mammal in need thereof. | 2021-10-07 |
20210308328 | TISSUE-BASED COMPOSITIONS AND METHODS OF USE THEREOF - Compositions comprising extracellular matrix (ECM) materials and methods of use thereof are disclosed. The compositions may comprise two or more ECM materials derived from different types of tissues, such as, e.g., lung tissue and spleen tissue, formulated for administration to a patient or configured as a medical device for implantation in or application to the patient. The compositions may combine complementary properties of different types of ECM materials for customized patient-specific and/or site-specific tissue repair and/or regeneration. | 2021-10-07 |
20210308329 | BIODEGRADABLE ARTICLES AND METHODS FOR TREATMENT OF PELVIC FLOOR DISORDERS INCLUDING EXTRACELLULAR MATRIX MATERIAL - Biodegradable implants including an ECM material and methods for treating a pelvic floor condition are described. ECM particles can be present within or on the surface of a pelvic implant, such as a biodegradable mesh, a pouch, or a urethral stent. After implantation the implant can provide tissue support, degrade over a period of time, and deposit the ECM material in the implantation area for regeneration of tissue and long term benefit. | 2021-10-07 |
20210308330 | Devices and Methods for Nerve Regeneration - A nerve regeneration device comprising a bioresorbable conduit and a matrix contained therein having elongate pores aligned with the longitudinal axis of the conduit. The matrix comprises collagen, fibronectin, laminin-1, and laminin-2, wherein the amount, by weight, of laminin-1 or laminin-2 is greater than the amount of fibronectin in the matrix. | 2021-10-07 |
20210308331 | MACROSCOPICALLY ALIGNABLE, INJECTABLE, SOFT HYDROGEL COMPOSITION - The present invention relates to a macroscopically alignable, injectable, soft hydrogel composition which is able to form an anisotropic structure in vivo, after injection, to generate healthy functioning tissue and regenerate injured or diseased soft tissue. | 2021-10-07 |
20210308332 | HYDROGEL COMPOSITIONS ENCAPSULATING SOLID PARTICLES - The present disclosure relates to compositions comprising hydrogels and solid particles and their use. More specifically, the proposed technique relates to methods for manufacturing of a composition comprising solid particles encapsulated within crosslinked polysaccharide molecules forming hydrogel particles, the method comprising mixing water-soluble polysaccharide molecules comprising one or more carboxyl groups, water insoluble solid particles, a di- or multinucleophilic functional crosslinker, and a coupling agent, in a water suspension at pH between 5 and 9, to form a composition comprising a hydrogel of crosslinked polysaccharide molecules encapsulating the solid particles. The disclosure comprises the composition, methods for producing the composition and use of the composition as a dermal filler. | 2021-10-07 |